2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14667S
    Lomitapide-d8 2459377-96-7 98%
    Lomitapide-d8 is deuterium labeled Lomitapide. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
    Lomitapide-d8
  • HY-146704
    COX-2/sEH-IN-1 2474977-38-1 98%
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
    COX-2/sEH-IN-1
  • HY-146731
    PPARγ agonist 1 3032632-09-7 98%
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders.
    PPARγ agonist 1
  • HY-147037
    AMPK activator 7 1623138-03-3 98%
    AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.
    AMPK activator 7
  • HY-147106
    Mrgx2 antagonist-1 2767110-35-8 98%
    Mrgx2 antagonist-1 (example 1) is a potent Mrgx2 (Mas-related Gene X2) antagonist. Mrgx2 antagonist-1 can be used for the research of MrgX2-mediated diseases and disorders.
    Mrgx2 antagonist-1
  • HY-147195
    QH536 2754254-07-2 98%
    QH536 (Compound 29) is a potent HMGCR degrader with an EC50 of 0.22 μM. QH536 has no side-effect of inducing cholesterol accumulation in cells. QH536 shows anti-inflammatory and can be used for cardiovascular disease and nonalcoholic steatohepatitis research.
    QH536
  • HY-147234
    Sirtuin modulator 2 667910-69-2 99.22%
    Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM.
    Sirtuin modulator 2
  • HY-147256
    Cavutilide 1276186-19-6 98%
    Cavutilide (Niferidil) is a class III antiarrhythmic agent that inhibits hERG K+ channel. Cavutilide has the potential for the study of persistent atrial fibrillation.
    Cavutilide
  • HY-147267
    Evazarsen 2589926-22-5
    Evazarsen is an angiotensinogen synthesis inhibitor and possesses antihypertensive properties.
    Evazarsen
  • HY-147299
    Povafonidine 177843-85-5 98%
    Povafonidine (PGE-6201204) is a potent α2 adrenoreceptor agonist. Povafonidine can constrict blood vessels and reduce mucosal congestion. Povafonidine can be used for nasal congestion research.
    Povafonidine
  • HY-147335
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester 845779-89-7 98%
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester is an orally active n-1PUFA. 6,9,12,15-Hexadecatetraenoic acid-ethyl ester intake can reduce plasma triglyceride content in mice.
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester
  • HY-147336
    Desmethylazelastine 47491-38-3 98%
    Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    Desmethylazelastine
  • HY-147377
    N-Salicyloyltryptamine 31384-98-2
    N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect-.
    N-Salicyloyltryptamine
  • HY-147393
    Factor VII-IN-1 244206-28-8 98%
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties.
    Factor VII-IN-1
  • HY-147406
    Tonlamarsen 2589926-20-3
    Tonlamarsen is a angiotensinogen synthesis reducer, with antihypertensive activity.
    Tonlamarsen
  • HY-14744B
    Levamlodipine hydrochloride 865430-76-8 98%
    Levamlodipine hydrochloride (Levoamlodipine hydrochloride) is a dihydropyridine calcium channel blocker. Levamlodipine hydrochloride reduces the inflow of calcium ions by blocking L-type calcium channels on vascular smooth muscle cells, thereby leading to vasodilation, lower blood pressure and lighten the burden on the heart. Levamlodipine hydrochloride has activity to lower blood pressure and relieve angina. The binding properties of Levamlodipine hydrochloride to human serum albumin (HSA) contribute to the study of drug transport and release mechanisms in the body.
    Levamlodipine hydrochloride
  • HY-14744C
    Levamlodipine hydrobromide 865430-78-0 98%
    Levamlodipine hydrobromide is the besylate hydrobromide salt form of Levamlodipine (HY-14744). Levamlodipine hydrobromide is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine hydrobromide can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine hydrobromide can be used for research on vascular dementia, hypertension, and cerebrovascular diseases.
    Levamlodipine hydrobromide
  • HY-147502
    Vin-C01 23173-26-4 98%
    Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 μM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research.
    Vin-C01
  • HY-147503
    Vin-F03 2180917-11-5 98%
    Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 μM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research.
    Vin-F03
  • HY-147574
    Axl-IN-7 1770821-83-4 98%
    Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.
    Axl-IN-7
Cat. No. Product Name / Synonyms Application Reactivity